U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07862582) titled 'RYZ711 Diagnostic Platform Study' on Oct. 01.
Brief Summary: This is a Phase 1/2 multicenter, multi-cohort imaging study to evaluate the safety, tolerability, and diagnostic performance of RYZ711 positron emission tomography/computed tomography (PET/CT) in men with histologically confirmed adenocarcinoma of the prostate.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Prostate Cancer (Adenocarcinoma)
Adenocarcinoma of the Prostate
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Biochemical Recurrence (BCR)
High-Risk Localized Prostate Cancer
Interven...